Search Results
Your search for early matches 10011 pages
Showing 501 - 550V. Craig Jordan, PhD, a Founding Father of Targeted Therapy in Cancer, Dies at Age 76
Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, a pioneering scientist whose innovative work in breast cancer research has saved countless lives and will continue to impact the field for generations to come, died on June 9, according to a news release from The University of Texas MD Anderson Cancer...
How Often Do Patients With Cancer Face Barriers When Attempting to Access Care?
Many patients with cancer encounter significant barriers to the receipt of care, according to a recent study published by Chen et al in JAMA Network Open. Background When attempting to access cancer care, patients often must go through several different levels of communication both before their...
Lung Cancer Screening May Improve Early Detection, Survival in U.S. Veterans
Investigators have found that U.S. veterans who underwent lung cancer screening prior to diagnosis were potentially more likely to be diagnosed with earlier-stage disease and have a higher cure rate compared with those who did not undergo screening, according to a recent study published by Edwards...
Cardiac Dysfunction Among Breast Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Bostany et al found that the cumulative incidence of cardiac dysfunction reached 15.3% at 15 years from the start of cardiotoxic treatments in breast cancer survivors. Study Details The study involved patients at the Next Steps Breast Cancer...
Lung Cancer Screening Prevalence Among Eligible U.S. Individuals
In a study reported in JAMA Internal Medicine, Bandi et al found that only 18% of eligible individuals in the United States were considered up to date—defined as undergoing screening within the past year—for recommended annual lung cancer screening in 2022. As stated by the investigators, “The U.S. ...
Guideline Update Seeks to Aid Clinicians in the Selection of Systemic Treatments for Advanced Hepatocellular Carcinoma
An ASCO guideline update offers new recommendations on systemic treatment for advanced hepatocellular carcinoma (HCC), based on promising findings from several recent randomized controlled trials as well as the approval of new first- and second-line immunotherapy combinations.1 “This guideline...
I Am Living With Recurring Stage IV Colorectal Cancer
Despite urgings from my primary care physician to get a colonoscopy screening after I turned 50, I resisted. As a health-care provider, and someone who is tuned into changes in my body, I thought I would instinctively know if I had a serious illness. I was wrong. Even after finally relenting to at...
In Celebration of a Remarkable Life and Career in Oncology
When Jamie H. Von Roenn, MD, FASCO, graduated from high school in 1970 and enrolled at the University of Illinois in Champaign, she was determined to seek a career in special education, because she wanted to “help people through difficult situations.” Although Dr. Von Roenn ultimately decided to...
Multiple Myeloma Survivor and Advocate Shares 12-Step Program: How Not to Die of Cancer
Facing mortality can be a paralyzing experience for some people, but for others, it may ignite a passion to accelerate life. One such person is Kathy Giusti, cofounder of the Multiple Myeloma Research Foundation (MMRF), where she served as Chief Executive Officer and President for nearly 20 years....
NADINA Trial Shows Robust Benefit for Neoadjuvant Nivolumab Plus Ipilimumab in Stage III Melanoma
Results of the phase III NADINA trial support a new standard of care for the treatment of resectable macroscopic stage III melanoma. Treatment with preoperative ipilimumab plus nivolumab followed by total lymph node dissection, with adjuvant therapy guided by depth of response, led to a highly...
Pancreatic Surgeon Named New Director of Moores Cancer Center at UC San Diego Health
Following an extensive national search, Diane M. Simeone, MD, has been appointed Director of Moores Cancer Center at the University of California (UC) San Diego Health. Dr. Simeone brings institutional, national, and international leadership experience both to oncologic patient care and scientific...
Cardiotoxicity: How Far Have We Come?
A little more than 12 months ago, the first major cardio-oncology guidelines were published by the European Society of Cardiology (ESC).1 The extensive document embodied the immense progress of this subspecialty over its short existence. In reaching this milestone, it is worth considering what...
Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC
Osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non–small-cell lung cancer (NSCLC) following definitive chemoradiotherapy. These findings of the phase III LAURA trial suggest that osimertinib may become a new...
Childhood Cancer Survivors: Burden of Cardiovascular Disease and Risk of Major Cardiovascular Events
In an analysis from the St. Jude Lifetime Cohort Study (SJLIFE) reported in The Lancet Oncology, Hammoud et al found that survivors of childhood cancer had a greater risk of major adverse cardiovascular events vs matched community controls, and that an increasing burden of nonmajor events increased ...
Study Finds Early Menopause May Be Linked to Greater Risk of Breast and Ovarian Cancers
The risk of breast cancer and ovarian cancer may be increased in some women who experience early menopause, according to new findings presented by Welt et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Primary ovarian insufficiency is a condition that occurs when a woman’s...
Neoadjuvant Pembrolizumab May Improve Outcomes in Some Patients With Colorectal Cancer Surgery
Researchers examined whether the PD-1 inhibitor pembrolizumab given neoadjuvantly may improve outcomes in certain patients with stage II or III mismatch repair–deficient/microsatellite instability–high colorectal cancer. Interim findings from the phase II NEOPRISM-CRC clinical trial were presented...
Aspirin as Adjuvant Therapy for Breast Cancer
As reported in JAMA by Wendy Y. Chen, MD, MPH, and colleagues, interim analysis of the phase III Alliance A011502 trial has shown no invasive disease–free survival benefit with adjuvant aspirin vs placebo in patients with high-risk nonmetastatic breast cancer. The trial was suspended early due to...
Dennis J. Slamon, MD, PhD, Awarded 2024 Szent-Györgyi Prize for Progress in Cancer Research
The National Foundation for Cancer Research (NFCR) announced that the blue-ribbon selection committee, composed of world-renowned research leaders and visionaries, has awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research to Dennis J. Slamon, MD, PhD, of UCLA Health, for his...
New Study Highlights Benefits of Stepped Palliative Care in Advanced Lung Cancer
Researchers have shown the effectiveness of more scalable ways of delivering palliative care in patients with advanced lung cancer, according to new findings published by Temel et al in JAMA and simultaneously presented at the 2024 ASCO Annual Meeting (Abstract 12000). Background More intensive...
Many Breast Cancer Survivors May Experience Excess Weight Gain
Nearly 20% of breast cancer survivors may experience weight gain of more than 10%, according to recent findings presented by Hurtado Andrade et al at the Endocrine Society’s Annual Meeting & Exposition 2024. The research may illuminate a number of factors potentially contributing to excessive...
Novel ctDNA Liquid Biopsy May Help Predict Breast Cancer Recurrence Years Before Relapse
A novel ultrasensitive liquid biopsy may be predictive of breast cancer recurrence up to years prior to relapse in high-risk patients with early breast cancer, according to recent findings presented by Garcia-Murillas et al at the 2024 ASCO Annual Meeting (Abstract 1010). Background Circulating...
Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).
Study Including Only Black Patients With Breast Cancer Compares Rates of Taxane-Induced Peripheral Neuropathy
New findings suggest that docetaxel may be considered the preferred treatment over paclitaxel for Black patients with early-stage breast cancer. While the EAZ171 trial focused specifically on Black people, the results highlight the need to personalize therapy to minimize toxicity. Importantly, this ...
Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for ...
Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment
Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).
Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection
Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay ...
USP1 Inhibitor in Metastatic Solid Tumors
The first-in-class ubiquitin-specific peptidase 1 (USP1) inhibitor RO7623066 showed a positive safety profile as a single agent and signs of early antitumor activity in patients with advanced solid tumors, according to preliminary data from a new first-in-human phase I trial presented by Yap et al...
Neoadjuvant Immunotherapy Combination Improves Outcomes in Patients With Melanoma
Neoadjuvant immunotherapy given for stage III melanoma—followed by adjuvant therapy only if there is not a deep response to treatment—may produce better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone. These results from the NADINA trial were presented ...
Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy
Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for...
Reshma Jagsi, MD, and Christian F. Singer, MD, MPH, on Early-Stage Breast Cancer: Adding a Vaccine to Neoadjuvant Systemic Therapy
Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Christian F. Singer, MD, MPH, of the Medical University of Vienna, discuss the MUC-1 vaccine tecemotide. When added to standard neoadjuvant systemic therapy for patients with early-stage breast cancer, this vaccine improved...
Consolidation Therapy With Durvalumab for Limited-Stage SCLC
Results from an interim analysis of the phase III ADRIATIC study demonstrated that consolidation therapy after chemoradiotherapy with durvalumab extends survival in patients with limited-stage small-cell lung cancer (SCLC) compared to the current standard-of-care treatment of chemoradiotherapy...
Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care
Joseph A. Greer, PhD, of Massachusetts General Hospital and Harvard Medical School, discusses study findings showing the merits of delivering early palliative care via telehealth vs in person to patients with advanced lung cancer. Using telemedicine in this way may potentially improve access to and ...
Telehealth Shown to Be Effective for Palliative Care Delivery in Patients With Advanced Lung Cancer
New research reinforces the telehealth delivery of palliative care as an effective alternative to in-person visits for patients with advanced lung cancer, providing comparable quality-of-life benefits. This research was presented by Joseph Greer, PhD, and colleagues at the 2024 ASCO Annual Meeting...
Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease
Denise A. Yardley, MD, of the Sarah Cannon Research Institute, discusses the NATALEE trial, which assessed ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) vs an NSAI alone in patients with hormone receptor–positive/HER2-negative early breast cancer at increased risk of recurrence,...
Combination BrECADD Is Significantly More Effective Than BEACOPP for Classical Hodgkin Lymphoma, Study Finds
Although advancements in the treatment of classical Hodgkin lymphoma have increased the 5-year relative survival rate of patients with the disease to nearly 90%, dose-intensified treatment strategies may increase the risk for acute and long-term toxicities. The German Hodgkin Study Group (GHSG)...
Shorter Durations of Venetoclax Yield Similar Response Rates Compared to Standard Course in AML
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible patients with newly diagnosed acute myeloid leukemia (AML). These results from a retrospective...
American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration
The American Cancer Society (ACS) and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership between ASCO, the leading organization for cancer care providers, and ACS, the leading patient education, support,...
A Father’s Advice Plus a Desire to Help Spur a Career in Oncology and a Leadership Role in African Cancer Care
Miriam Mutebi, MD, MSc, FACS, was born and reared in the outskirts of Nairobi, Kenya. “The suburb I grew up in (Langata), has seen a lot of development over the past couple of decades. When I was a child, it was a smaller community, where you would go and play at somebody else’s house and have...
For an International Expert in Gynecologic Cancer, Being Reared by Educators Who Stressed Knowledge and Service Was Key
Deputy Editor of The ASCO Post, Jame Abraham, MD, FACP, recently spoke with gynecologic cancer expert Sharmila K. Makhija, MD, MBA, about her journey to her current position as Founding Dean and Chief Executive Officer of the Alice L. Walton School of Medicine, Bentonville, Arkansas. Raised by...
Immigrant Reared During the Lebanese Civil War by Parents Who Valued Education Becomes a Leader in Genitourinary Oncology
Genitourinary cancer expert Toni K. Choueiri, MD, FASCO, was born in 1975 in Beirut, Lebanon, the year a devastating civil war erupted, lasted for 15 years, and cost the lives of some 150,000 individuals and also led to the exodus of almost 1 million people from Lebanon. “People with the financial...
Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond
Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...
The National Cancer Act of 1971 Inspired a Career in Service to and Advocacy for Patients With Cancer
ASCO President for the 2024–2025 term, Robin Zon, MD, FACP, FASCO, was born and reared in Cheektowaga, a town in the western part of New York. “Cheektowaga is the Native American name for ‘land of the crabapple tree.’ Western New York was first settled by one of seven tribes belonging to the...
A Mother’s Encouragement and a Husband-Wife Doctor Team Set the Stage for a Career in Hematologic Oncology
Lymphoma expert Jane N. Winter, MD, grew up on the south shore of Long Island in New York. “My dad sold cars in my great uncle’s dealership after a failed foray into business after World War II. My mom graduated high school at 16 to go to work to help support her family. When my younger brother...
A Daughter of First-Generation Immigrants Follows Their Can-Do Philosophy in Her Research Efforts in Hematologic Oncology
Leukemia expert Eunice S. Wang, MD, is the daughter of first-generation immigrants, whose work ethos inspired in her a world without boundaries. “My parents were born in China during the communist era, and they immigrated to Taiwan when the communists took over in the 1940s and then subsequently...
Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference
ASCO President-Elect Eric J. Small, MD, FASCO, developed much of his multicultural world view during his childhood in Mexico City. “My parents were expatriates who moved to Mexico in the 1950s and settled there. I was born in Mexico City and grew up bilingually. I went to an English-Spanish...
Be Prepared: A Patient Perspective
I’m not prepared. It could be a few months, a few years, maybe longer. I don’t know how bad the verdict will be, but whatever it is, I’m not prepared. They always told us to be prepared. That was our motto. At age 7, I joined the Brownies, the beginning of 12 years of being molded by Girl Scout...
Early Breast Cancer: ALND or SLNB for ypN-Positive Disease After Neoadjuvant Chemotherapy
In an analysis of clinical trials reported in a research letter in JAMA Oncology, Brooks et al found no differences in long-term outcomes with the use of axillary lymph node dissection (ALND) vs sentinel lymph node biopsy (SLNB)—usually paired with adjuvant radiotherapy—among patients with breast...
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist...
The Future of Cancer Care
The profound progress in cancer care since President Richard Nixon signed the National Cancer Act of 1971 into law is evidenced by the soaring number of cancer survivors since the law went into effect. In the 1970s, there were 3 million cancer survivors1; today, there are more than 18 million, and...
Is a Test for Early Detection of Pancreatic Cancer on the Horizon?
An investigational noninvasive exosome-based liquid biopsy shows potential for early detection of pancreatic cancer, an important unmet need, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.1 When combined with the biomarker CA 19-9, the...
